Section(X) | Body System(W) | Operation(0) | Qualifier(5) | Device / Substance / Technology(M) | Approach(7) | |
New Technology | Anatomical Regions | Introduction | New Technology Group 5 | Brexucabtagene Autoleucel Immunotherapy | Via Natural or Artificial Opening | |
No record found
Change Type | Change Date | Previous Descriptor |
Code Deleted | 09-30-2024 | Introduction of Esketamine Hydrochloride into Nose, Via Natural or Artificial Opening, New Technology Group 5 |
Code Added | 10-01-2020 |